CYTALUX™for the Intraoperative Imaging of Prostate Cancer
An Investigator Sponsored Study to Investigate the Safety and Efficacy of CYTALUX™ (PAFOLACIANINE) INJECTION for the Intraoperative Imaging of Prostate Cancer
Sponsor: Indiana University
Listed as NCT06434909, this PHASE2 trial focuses on Prostate Cancer and remains completed. Sponsored by Indiana University, it has been updated 8 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE2
Status: Recruiting → Completed · Phase: PHASE1 → PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE1
-
May 2025 — Oct 2025 [monthly]
Recruiting PHASE1
-
Feb 2025 — May 2025 [monthly]
Recruiting PHASE1
Phase: PHASE2 → PHASE1
-
Oct 2024 — Feb 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting · Phase: EARLY_PHASE1 → PHASE2
▶ Show 3 earlier versions
-
Sep 2024 — Oct 2024 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Indiana University
- On Target Laboratories, LLC
For direct contact, visit the study record on ClinicalTrials.gov .